Randomized Controlled Trial on the Efficacy of Reduced-Dose Cyclical Corticosteroids and Cyclophosphamide in Primary Membranous Nephropathy.

ABSTRACT:

Introduction

The use of cyclophosphamide with corticosteroids for the management of membranous nephropathy (MN) is associated with significant safety concerns. Several retrospective studies suggest that a lower dose may effectively induce remission in participants with MN. This randomized trial assessed whether the lower dose of cyclical cyclophosphamide/corticosteroids was noninferior to the standard dose in patients with MN.

Methods

We randomly assigned 114 participants (32 women and 82 men) to receive either the low dose (prednisolone, 0.5 mg/kg/d during months 1, 3, and 5 along with oral cyclophosphamide, 1.0-1.5 mg/kg/d during months 2, 4, and 6) or the standard-dose cyclophosphamide/corticosteroids (methylprednisolone, 1 g/d for 3 days, followed by prednisolone, 0.5 mg

SUBMITTER: Ramachandran R 

PROVIDER: S-EPMC12639806 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature